Abstract
AbstractTimely and correct assessment of histopathological, immunohistochemical and molecular features of biopsy and surgical specimens is of paramount importance in the provision of care to patients with breast cancer, particularly in the current era of precision oncology. In order to ensure that tissue samples are obtained, processed, analyzed and reported in an optimal way, a concerted effort is required by institutions and individuals, taking into account state-of-the-art scientific and technical knowledge and circumventing logistic and operational constraints. This may be particularly challenging in some settings due to several sources of economic, structural, organizational and communication inefficiencies. In the current article, we present a brief review of breast cancer epidemiology and challenges in the disease diagnosis, especially in Brazil, and report the results of a multidisciplinary working group convened in May 2020 in an expert panel to identify and discuss the barriers and challenges related to the journey of breast cancer samples in Brazil. Following the identification of the issues, the working group also discussed and proposed recommendations for improving the journey and quality of breast cancer samples based on their professional experience and the current scientific literature, including guidelines of national and international health organizations (e.g. World Health Organization), consensus of medical societies and other published literature on the topic. We outline the most salient issues related to that journey in Brazilian public and private medical institutions, based on the experts’ clinical experience, since all of them are actively working at both sectors, and discuss current recommendations to address these issues aiming at mitigating and preventing preanalytical and analytical issues affecting diagnostic and therapeutic decisions. Such issues are grouped under four headings pertaining to education, communication, procedures in the operating room and sample transportation, and procedures in the pathology laboratory. Selected recommendations based on the current literature and discussed by the group of Brazilian experts are reviewed, which may mitigate the issues identified and optimize diagnostic and therapeutic decisions for patients with breast cancer, currently the most frequent malignant tumor worldwide and in Brazil. This paper has been submitted and published jointly, upon invitation and consent, in both the Surgical and Experimental Pathology and the Mastology journals.
Funder
Roche Produtos Químicos e Farmacêuticos
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–66.
2. Assis E. Manual de Boas Práticas em Patologia. São Paulo: Sociedade Brasileira de Patologia, 2020. http://www.sbp.org.br/publicacoes/manual-de-boas-praticas-em-patologia/. Accessed on 09 February 2022.
3. Burstein HJ, Curigliano G, Thurlimann B, Weber WP, Poortmans P, Regan P, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International consensus guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32:1216–35.
4. Brasil. Agência Nacional de Saúde Suplementar. Dados Gerais. Beneficiários de planos privados de saúde, por cobertura assistencial (Brasil – 2011–2021). Available at https://www.gov.br/ans/pt-br/acesso-a-informacao/perfil-do-setor/dados-gerais (Accessed 09 February 2022).
5. Brasil. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020 : incidência de câncer no Brasil. Rio de Janeiro: INCA, 2019. Available at https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf(Accessed 09 February 2022).